UNSPSC 51293402: Bupropion

This classification denotes an antidepressant agent with the molecular formula C13H18ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 01ZG3TPX31, chemically known as 1-propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)- but generally known as bupropion, which bears US NIH Compound Identifier 444. Bupropion most often comes in base and hydrochloride forms. European Medicines Agency schedules Bupropion in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05413MIG.

UNSPSC 51293402 Bupropion is a Commodity code covering individual pharmaceutical products, but recent state and local solicitations tagged under this code reflect broader pharmaceutical procurement activity: naloxone and drug deactivation systems for public health emergency response, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing frameworks, and direct-to-manufacturer prescription program capabilities. The work being solicited ranges from immediate supply of specific medications and harm-reduction supplies to strategic vendor-capability assessments for redesigned pharmacy benefit delivery models. State and local governments issuing under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances spanning multiple states (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions).

Recent activity concentrates in the South and Upper Midwest. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023 per notice date, though with conflicting timeline information) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries with a two-year initial term and one-year renewal option. The Texas HHS Commission issued an RFI on April 3, 2026 for Direct-to-Manufacturer Prescriptions capabilities to inform future formal procurement strategy. The Minnesota Department of Administration's MMCAP issued an RFP on January 20, 2026 (due March 26, 2026) to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with awarded vendors effective July 1, 2026; vendors must work through three authorized wholesalers, achieve cGMP and Drug Supply Chain Security Act compliance, and carry commercial general liability of $5,000,000 per occurrence. These recent opportunities show states and local public-health bodies actively sourcing medications and related supplies through both routine IFBs and cooperative purchasing vehicles.